Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

95.850
-2.200-2.24%
Volume:6.83M
Turnover:644.53M
Market Cap:167.26B
PE:203.94
High:96.600
Open:94.200
Low:92.400
Close:98.050
52wk High:112.700
52wk Low:69.550
Shares:1.75B
HK Float Shares:1.75B
Volume Ratio:0.82
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.470
ROE:7.01%
ROA:2.23%
PB:6.89
PE(LYR):203.94
PS:9.10

Loading ...

Innovent Biologics Slashes Prices on Weight-Loss Drug as Growth Concerns Mount

Deep News
·
Aug 10

Movement Alert|INNOVENT BIO Rises 3.06% in Regular Trading, H1 Revenue Significantly Beats Expectations as Multiple Banks Raise Target Prices

Market Focus
·
Aug 10

Innovent Biologics Signs Exclusive Deal with Daiichi Sankyo to Commercialize Vanflyta in China

Reuters
·
Aug 10

Biotech ETF Gains Over 5% as Leading Innovators Report Strong Earnings and Global Supply Chain Remains Robust

Stock News
·
Aug 07

Movement Alert|INNOVENT BIO Rises 3.02% in Regular Trading, Multiple Banks Raise Target Prices on Strong Revenue Beat and Pipeline Progress

Market Focus
·
Aug 07

Goldman Sachs Lifts INNOVENT BIO Target to HKD 111.68 on Strong H1 Product Revenue Growth

Stock News
·
Aug 06

Innovent Announces First Patient Dosed in Pivotal Registrational Study of Ibi363/Tak-928 (Pd-1/Il-2Α-Biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

THOMSON REUTERS
·
Aug 06

Citigroup Maintains Bullish Stance on INNOVENT BIO with HK$115 Price Target

Deep News
·
Aug 05

CLSA: INNOVENT BIO (01801) First-Half Product Revenue Significantly Exceeds Expectations, Serving as a Positive Catalyst for Stock Price

Stock News
·
Aug 05

Innovent Biologics' Product Revenue Surges 60% in Q2

MT Newswires Live
·
Aug 05

Innovent Biologics Jumps Most in 3 Weeks on Robust Product Revenue Growth

Reuters
·
Aug 05

INNOVENT BIO shares open over 2% higher as first-half product revenue exceeds RMB 8.2 billion, marking a 55% surge

Stock News
·
Aug 05

Movement Alert|INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth

Market Focus
·
Aug 05

Hong Kong Listed Companies' News Digest: Innovent Bio's First-Half Product Revenue Exceeds RMB 8.2 Billion, Up Over 55% Year-on-Year

Stock News
·
Aug 05

Innovent Biologics Says First Half 2026 Product Revenue Exceeds Rmb8.2 Billion

Reuters
·
Aug 05

Innovent reports H1 2026 product revenue surpassing RMB 8.20 billion, up more than 55%; Q2 alone tops RMB 4.30 billion with 60% growth

Bulletin Express
·
Aug 05

Innovent Biologics - First Half 2026 Product Revenue Exceeds Rmb8.2 Bln, up over 55% Y/Y

THOMSON REUTERS
·
Aug 05

Movement Alert|INNOVENT BIO Declines 3.52% in Regular Trading, Trading at 83.5 HKD

Market Focus
·
Aug 03

Medtide Names Ding Lijun as CFO

Reuters
·
Jul 31

China's domestic innovative drugs set for overseas revenue breakthrough as policy support strengthens

Stock News
·
Jul 31